Ray is Co-founder and Senior Director of Drug Discovery Platform Technology at Kimia. He leads a diverse team in the design and application of high-throughput chemical synthesis and screening technologies for Kimia's innovative ATLAS platform.

Ray's extensive background in platform innovation includes his tenure as Director of Platform Technology at Carmot Therapeutics. In this pivotal role, he was essential to the creation and success of Chemotype Evolution, a groundbreaking direct-to-biology (D2B) drug discovery platform. This work proved highly impactful, contributing to the discovery of Roche’s current clinical-stage GLP-1R agonists and Amgen’s pioneering KRAS-targeting drug, LUMAKRAS™.

His expertise in building pioneering discovery engines was also demonstrated during his time at Sunesis Pharmaceuticals, where he focused on developing fragment-based tethering technology, and at Sirna Therapeutics/Merck, advancing RNAi-small molecule hybrid technologies.

Ray earned his MS in Molecular Biology from the University of Iowa and is an inventor on multiple patents and the author of over 20 scientific publications.